Phenylketonuria (PKU)

What changes during this transition

Phenylketonuria is an autosomal recessive inborn error of metabolism caused by biallelic mutations in PAH (phenylalanine hydroxylase, 12q23.2). Loss of PAH function prevents conversion of phenylalanine to tyrosine, producing toxic Phe accumulation in blood and brain — and, untreated from birth, severe intellectual disability, microcephaly, seizures, eczematous skin, and the characteristic musty body odor. Incidence is roughly 1 in 10,000-15,000 live births in most populations, higher in Turkey, Ireland, and Italy. Newborn screening (the Guthrie blood-spot test) has been universal since the 1960s and is one of the genuine public-health successes of the modern era: it converted PKU from inevitable severe disability into a manageable chronic disease, provided treatment starts at birth. Severity stratifies as classic PKU (untreated Phe >1200 µmol/L; strict lifelong dietary restriction), moderate PKU (Phe 600-1200 µmol/L), and mild hyperphenylalaninemia (<360 µmol/L; often no treatment needed). The differential includes BH4 cofactor deficiencies (PTPS, DHPR, GTPCH1 mutations) — they present similarly on newborn screening but require different management including neurotransmitter precursor replacement, so confirmatory workup matters. Standard of care is load-bearing dietary: lifelong phenylalanine-restricted diet (strict avoidance of meat, dairy, eggs, nuts, legumes, grains, and aspartame), Phe-free medical-food protein substitutes, low-protein modified foods, intensive dietitian management, and metabolic clinic follow-up. Treatment targets vary by jurisdiction and age — pediatric Phe 120-360 µmol/L is widely shared; adult targets cluster around <600 µmol/L in US guidance, with UK and several European jurisdictions historically recommending stricter lifelong treatment. The psychosocial burden is enormous: dietary restriction lifelong, teenage and young-adult nonadherence common, and maternal PKU syndrome (women with poorly-controlled PKU during pregnancy produce fetal microcephaly, intellectual disability, congenital heart disease, and IUGR regardless of fetal genotype) makes pre-pregnancy Phe control a critical decision point. Two FDA-approved adjuncts reduce the dietary burden. **Sapropterin dihydrochloride (Kuvan, BioMarin)** is a synthetic BH4 cofactor approved in 2007 for BH4-responsive PKU; roughly 30-50% of patients with partial residual PAH function respond, and it loosens but doesn't eliminate dietary restriction. **Pegvaliase (Palynziq, BioMarin) is the transformative peptide/protein therapy for adult PKU** — a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme administered subcutaneously, FDA-approved in May 2018 for adults with Phe >600 µmol/L. It bypasses the PAH defect entirely by introducing an alternative enzymatic pathway (Phe → trans-cinnamic acid + ammonia via PAL), works even in patients with severe PAH mutations who are not BH4-responsive, and in the Phase 3 PRISM trials produced substantial Phe reduction in roughly 70% of treated patients. The trade-off is a REMS program due to anaphylaxis risk (~3-5% of patients), careful induction with monitoring, and adverse events including injection-site reactions, arthralgia, and hypersensitivity. Pegvaliase's 2018 approval was genuinely transformative for the adult PKU community — for the first time, an alternative to dietary restriction alone became available. mRNA and gene therapy are in clinical trials. Community peptide framing reaches PKU sideways — through GH-axis peptides for pediatric growth (somatropin in confirmed GHD is established pediatric endocrinology; community GHRH/GHRP peptides are not interchangeable), BPC-157 for the skin and GI symptoms that poorly-controlled PKU produces (those are a Phe-control signal, not a separate injury), NMN for general health (uncharacterized in the PAH-null metabolic state). None engage the metabolic defect. Substrate exists for honest /ask answers when users probe — pegvaliase and sapropterin are the named standard-of-care peptide and small-molecule therapies; the community peptides are not appropriate to elevate as discovery cards for PKU. Editorial sensitivity: PKU is diagnosed at birth, dietary restriction is a lifelong psychosocial burden carried by patients and families, maternal PKU pregnancy decisions are emotionally significant, and multi-jurisdictional guideline variation (UK and several European jurisdictions historically stricter than US adult guidance) is real and ongoing. Patient advocacy: National PKU Alliance (npkua.org), European Society for Phenylketonuria, Children's PKU Network, International PKU Federation. Clinical guidelines: American College of Medical Genetics, Endocrine Society, European PKU guidelines (2017). Seventy-third deliberate non-elevation of community peptides.